Solésence Expands Debt Facilities to Fuel Growth Initiatives

Written by Emily J. Thompson, Senior Investment Analyst

Source: Newsfilter

Updated: Jun 02 2025

0mins

SLSN-2.78%

Should l Buy SLSN?

Source: Newsfilter

Loan Agreement Amendments: Solésence, Inc. has amended its loan agreements to increase borrowing capacity from $14.2 million to $23.0 million and extended the maturity date to April 30, 2027, providing financial flexibility for strategic objectives.
Company Overview: Solésence is a leader in health care solutions within beauty and life sciences, focusing on innovative mineral-based sun protection and empowering brand partners through enhanced product offerings.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy SLSN?" and start using high-conviction signals backed by rigorous historical data.

Analyst Views on SLSN

About SLSN

Solesence, Inc., formerly Nanophase Technologies Corporation, provides healthcare solutions across beauty and life science categories. It is a developer and manufacturer of clean, inclusive, mineral-based skincare and makeup products. The Company partners with global and indie brands, leveraging its proprietary Active Stress Defense technology suite (Original Active Stress Defense, Kleair, and Bloom) to bring environmental protection beauty products to market via over a dozen market-ready offerings that embrace self-expression, health care, and self-care across skin care and color cosmetic categories. It also offers custom development, with turnkey options available across all paths to market. The Company’s products are formulated using its own mineral sunscreen actives, which are produced in its Chicagoland facility where it has been producing sunscreen actives, including the zinc oxide sunscreen active.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Nanophase Technologies GAAP EPS of $0.04, revenue of $20.4M

Jul 31 2025SeekingAlpha

Financial Performance: Nanophase Technologies reported a Q2 GAAP EPS of $0.04 and revenue of $20.4 million.
Market Developments: Solesence, Inc. is experiencing growth but faces stock price challenges, while other materials stocks are joining the Russell Microcap Index.